Professional Marketing briefs

Share this article:
Romark Laboratories received a warning letter from the FDA regarding its product Alinia (nitazoxanide). The FDA charged that the sales aid and oral statements for Alinia are false or misleading because they promote unapproved uses and broaden the indication for Alinia, make unsubstantiated superiority claims, omit and minimize the risks associated with Alinia and/or make misleading compliance claims.

Roche added a new component to its $14 million diabetes education campaign, which pairs healthcare practitioners with Roche staff. “Creative Coaching” helps healthcare professionals with “the art of patient engagement.” Roche manufactures the Accu-Chek line of blood glucose monitors. The professional education program, Behavior Change through Patient Engagement, is multifaceted and includes a website with online tools and information.

San Mateo, CA-based Epocrates unveiled an OTC drug module that will allow clinicians to access the latest information for hundreds of brand name OTC drugs right from their iPhone, BlackBerry, Palm or Windows device. The OTC drug module is already used by more than 625,000 in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?